Cargando…

Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity

BACKGROUND: Cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,23(OH)(2)D3, as well as 1-hydroxyvitamin D3 to 1α,20-dihydroxyvitamin D3 (1,20(OH)(2)D3). It also cleaves the side chain of 7-dehydrocholesterol producing 7-dehydropregnenolone (7DHP), which can be transf...

Descripción completa

Detalles Bibliográficos
Autores principales: Slominski, Andrzej T., Janjetovic, Zorica, Fuller, Brian E., Zmijewski, Michal A., Tuckey, Robert C., Nguyen, Minh N., Sweatman, Trevor, Li, Wei, Zjawiony, Jordan, Miller, Duane, Chen, Tai C., Lozanski, Gerard, Holick, Michael F.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845617/
https://www.ncbi.nlm.nih.gov/pubmed/20360850
http://dx.doi.org/10.1371/journal.pone.0009907
_version_ 1782179420192112640
author Slominski, Andrzej T.
Janjetovic, Zorica
Fuller, Brian E.
Zmijewski, Michal A.
Tuckey, Robert C.
Nguyen, Minh N.
Sweatman, Trevor
Li, Wei
Zjawiony, Jordan
Miller, Duane
Chen, Tai C.
Lozanski, Gerard
Holick, Michael F.
author_facet Slominski, Andrzej T.
Janjetovic, Zorica
Fuller, Brian E.
Zmijewski, Michal A.
Tuckey, Robert C.
Nguyen, Minh N.
Sweatman, Trevor
Li, Wei
Zjawiony, Jordan
Miller, Duane
Chen, Tai C.
Lozanski, Gerard
Holick, Michael F.
author_sort Slominski, Andrzej T.
collection PubMed
description BACKGROUND: Cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,23(OH)(2)D3, as well as 1-hydroxyvitamin D3 to 1α,20-dihydroxyvitamin D3 (1,20(OH)(2)D3). It also cleaves the side chain of 7-dehydrocholesterol producing 7-dehydropregnenolone (7DHP), which can be transformed to 20(OH)7DHP. UVB induces transformation of the steroidal 5,7-dienes to pregnacalciferol (pD) and a lumisterol-like compounds (pL). METHODS AND FINDINGS: To define the biological significance of these P450scc-initiated pathways, we tested the effects of their 5,7-diene precursors and secosteroidal products on leukemia cell differentiation and proliferation in comparison to 1α,25-dihydroxyvitamin D3 (1,25(OH)(2)D3). These secosteroids inhibited proliferation and induced erythroid differentiation of K562 human chronic myeloid and MEL mouse leukemia cells with 20(OH)D3 and 20,23(OH)(2)D3 being either equipotent or slightly less potent than 1,25(OH)(2)D3, while 1,20(OH)(2)D3, pD and pL compounds were slightly or moderately less potent. The compounds also inhibited proliferation and induced monocytic differentiation of HL-60 promyelocytic and U937 promonocytic human leukemia cells. Among them 1,25(OH)(2)D3 was the most potent, 20(OH)D3, 20,23(OH)(2)D3 and 1,20(OH)(2)D3 were less active, and pD and pL compounds were the least potent. Since it had been previously proven that secosteroids without the side chain (pD) have no effect on systemic calcium levels we performed additional testing in rats and found that 20(OH)D3 had no calcemic activity at concentration as high as 1 µg/kg, whereas, 1,20(OH)(2)D3 was slightly to moderately calcemic and 1,25(OH)(2)D3 had strong calcemic activity. CONCLUSIONS: We identified novel secosteroids that are excellent candidates for anti-leukemia therapy with 20(OH)D3 deserving special attention because of its relatively high potency and lack of calcemic activity.
format Text
id pubmed-2845617
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-28456172010-04-02 Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity Slominski, Andrzej T. Janjetovic, Zorica Fuller, Brian E. Zmijewski, Michal A. Tuckey, Robert C. Nguyen, Minh N. Sweatman, Trevor Li, Wei Zjawiony, Jordan Miller, Duane Chen, Tai C. Lozanski, Gerard Holick, Michael F. PLoS One Research Article BACKGROUND: Cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,23(OH)(2)D3, as well as 1-hydroxyvitamin D3 to 1α,20-dihydroxyvitamin D3 (1,20(OH)(2)D3). It also cleaves the side chain of 7-dehydrocholesterol producing 7-dehydropregnenolone (7DHP), which can be transformed to 20(OH)7DHP. UVB induces transformation of the steroidal 5,7-dienes to pregnacalciferol (pD) and a lumisterol-like compounds (pL). METHODS AND FINDINGS: To define the biological significance of these P450scc-initiated pathways, we tested the effects of their 5,7-diene precursors and secosteroidal products on leukemia cell differentiation and proliferation in comparison to 1α,25-dihydroxyvitamin D3 (1,25(OH)(2)D3). These secosteroids inhibited proliferation and induced erythroid differentiation of K562 human chronic myeloid and MEL mouse leukemia cells with 20(OH)D3 and 20,23(OH)(2)D3 being either equipotent or slightly less potent than 1,25(OH)(2)D3, while 1,20(OH)(2)D3, pD and pL compounds were slightly or moderately less potent. The compounds also inhibited proliferation and induced monocytic differentiation of HL-60 promyelocytic and U937 promonocytic human leukemia cells. Among them 1,25(OH)(2)D3 was the most potent, 20(OH)D3, 20,23(OH)(2)D3 and 1,20(OH)(2)D3 were less active, and pD and pL compounds were the least potent. Since it had been previously proven that secosteroids without the side chain (pD) have no effect on systemic calcium levels we performed additional testing in rats and found that 20(OH)D3 had no calcemic activity at concentration as high as 1 µg/kg, whereas, 1,20(OH)(2)D3 was slightly to moderately calcemic and 1,25(OH)(2)D3 had strong calcemic activity. CONCLUSIONS: We identified novel secosteroids that are excellent candidates for anti-leukemia therapy with 20(OH)D3 deserving special attention because of its relatively high potency and lack of calcemic activity. Public Library of Science 2010-03-26 /pmc/articles/PMC2845617/ /pubmed/20360850 http://dx.doi.org/10.1371/journal.pone.0009907 Text en Slominski et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Slominski, Andrzej T.
Janjetovic, Zorica
Fuller, Brian E.
Zmijewski, Michal A.
Tuckey, Robert C.
Nguyen, Minh N.
Sweatman, Trevor
Li, Wei
Zjawiony, Jordan
Miller, Duane
Chen, Tai C.
Lozanski, Gerard
Holick, Michael F.
Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity
title Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity
title_full Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity
title_fullStr Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity
title_full_unstemmed Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity
title_short Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity
title_sort products of vitamin d3 or 7-dehydrocholesterol metabolism by cytochrome p450scc show anti-leukemia effects, having low or absent calcemic activity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845617/
https://www.ncbi.nlm.nih.gov/pubmed/20360850
http://dx.doi.org/10.1371/journal.pone.0009907
work_keys_str_mv AT slominskiandrzejt productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity
AT janjetoviczorica productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity
AT fullerbriane productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity
AT zmijewskimichala productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity
AT tuckeyrobertc productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity
AT nguyenminhn productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity
AT sweatmantrevor productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity
AT liwei productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity
AT zjawionyjordan productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity
AT millerduane productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity
AT chentaic productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity
AT lozanskigerard productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity
AT holickmichaelf productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity